Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.

  • Revenue in JPY (TTM)3.20tn
  • Net income in JPY180.63bn
  • Incorporated1925
  • Employees47.50k
  • Location
    Takeda Pharmaceutical Co Ltd4F, 2-1-1, Nihombashihon-choCHUO-KU 103-8668JapanJPN
  • Phone+81 332782111
  • Fax+81 332782000
  • Websitehttps://www.takeda.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
4502:TYO since
Nihon Pharmaceutical Co LtdAnnounced24 Nov 202024 Nov 2020Announced2.36%51.04m
Data delayed at least 20 minutes, as of Mar 03 2021 00:05 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Astellas Pharma Inc1.25tn138.31bn3.18tn15.88k22.992.3215.132.5474.4174.41674.20736.790.58471.593.5278,902,980.006.4510.568.6914.0580.6276.9511.0415.091.11--0.221136.12-0.42140.8448-12.087.54-0.82115.92
Alexion Pharmaceuticals, Inc.648.02bn64.42bn3.57tn3.84k56.412.8635.825.502.692.6927.4053.080.34060.78894.581,581,939.003.395.303.685.7190.8890.689.9417.953.1146.650.18030.0021.6118.44-74.9033.11-17.92--
Takeda Pharmaceutical Co Ltd3.20tn180.63bn5.70tn47.50k31.431.227.631.78114.96114.962,035.142,965.000.25271.283.9767,359,510.001.431.631.692.0769.0968.865.645.
Bayer AG5.33tn-2.00tn6.61tn99.54k--1.68--1.24-15.84-10.6842.1731.070.34041.773.90415,921.60-12.80-0.9407-17.01-1.2053.7760.72-37.59-2.480.67257.150.5764---4.93-2.12-751.15---0.7993-4.06
Chugai Pharmaceutical Co Ltd786.95bn214.73bn8.01tn7.39k36.548.00--10.18130.53130.53478.34596.160.6861.553.62--18.7212.7622.8615.2165.2557.6327.2919.272.76195.73--45.4714.689.5536.2928.5719.4425.98
Data as of Mar 03 2021. Currency figures normalised to Takeda Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

16.17%Per cent of shares held by top holders
HolderShares% Held
Nomura Asset Management Co., Ltd.as of 29 Jan 202163.99m4.06%
The Vanguard Group, Inc.as of 31 Jan 202139.13m2.48%
Daiwa Asset Management Co. Ltd.as of 29 Jan 202129.98m1.90%
Nikko Asset Management Co., Ltd.as of 29 Jan 202129.23m1.85%
BlackRock Fund Advisorsas of 04 Feb 202125.85m1.64%
Norges Bank Investment Managementas of 31 Dec 201924.02m1.52%
Mitsubishi UFJ Kokusai Asset Management Co., Ltd.as of 04 Feb 202114.11m0.90%
T. Rowe Price International Ltd.as of 31 Dec 202010.16m0.65%
Templeton Global Advisors Ltd.as of 31 Jan 20219.23m0.59%
Baillie Gifford & Co.as of 26 Feb 20219.20m0.58%
More ▼
Data from 31 Dec 2019 - 31 Dec 2020Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.